Corbus Pharma reports positive top-line data for obesity treatment
Corbus Pharmaceuticals said top-line study data for its obesity treatment showed statistically significant, clinically meaningful weight loss, including a mean 5% loss at 12 weeks for a 60-milligram dose of CRB-913.